Navigation Links
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
Date:10/17/2011

modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
4. Ondine Biopharma Announces Second Quarter 2008 Financial Results
5. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Therapure Biopharma Inc. opens for business with first client contracts
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. China Biopharma Effects 1 for 100 Reverse Stock Split
11. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... for the second quarter 2015 on Monday, August 10, ... Helen Torley , president and chief executive officer, will ... will release financial results for the second quarter 2015. ... the "Investors" section of Halozyme,s corporate website and a ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
(Date:8/3/2015)... 2015 At the 11th hour, ... waved the shortfall of Jude Liversage,s campaign ... the first time.      (Photo: http://photos.prnewswire.com/prnh/20150803/254228 ... ) The Selective Dorsal Rhizotomy (SDR) procedure ... carry out his wish to kick a ball around ...
(Date:8/3/2015)... Ga. , Aug. 3, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... present at the 35 th Annual Canaccord|Genuity Growth ... H. "Pete" Petit, Chairman and CEO, William C. ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... FRANCISCO, Calif., Aug. 15, 2011 diaDexus, Inc. (OTC Bulletin ... the development and commercialization of patent-protected in vitro ... financial results for the second quarter of 2011. ... $3.8 million, representing 45% growth over total revenues of $2.6 ...
... Aug. 15, 2011 A new post-hoc sub-analysis of ... study – those identified as the "core clinical cohort" ... with aspirin) was associated with a 26 percent relative ... death, myocardial infarction or stroke, compared to treatment with ...
... SAN DIEGO, Aug. 15, 2011 NexBio announced top ... DAS181, an investigational drug for treatment and prophylaxis of ... of influenza and parainfluenza viruses, including pandemic influenza strains. ... healthy adults infected with influenza virus, treatment with DAS181 ...
Cached Biology Technology:diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 2diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 3diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 4diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Yale University have discovered that a specialized receptor, normally ... throughout the body, sensing small molecules created by microbes ... by increasing blood pressure. The finding suggests that gut ... system for maintaining a stable blood pressure. A ...
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... from Michigan State University have successfully engineered a plant with ... as well as lead to improved animal feeds. The ... Cell , the journal of the American Society of Plant ... in oil production to engineer a plant that stores lipids ...
Cached Biology News:Blood vessels 'sniff' gut microbes to regulate blood pressure 2Blood vessels 'sniff' gut microbes to regulate blood pressure 3Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2'Fat worms' inch scientists toward better biofuel production 2
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
nuclear RNA export factor 1, mRNA...
Biology Products: